SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Chronic lymphocytic leukemia (CLL) exhibits variable clinical courses, necessitating markers for aggressive disease identification.
• The costimulatory molecule and microbial sensor SLAMF1 (CD150) plays a role in immune cell function.

Purpose of the Study:

• To investigate the role of SLAMF1 expression in CLL aggressiveness and patient outcomes.
• To elucidate the functional consequences of SLAMF1 loss in CLL cells, including effects on cell migration and autophagy.

Main Methods:

• Analysis of SLAMF1 expression in CLL patient subsets.
• In vitro studies using SLAMF1-silenced CLL-like Mec-1 cells.
• Investigation of signaling pathways, chemotaxis, and autophagy induction upon SLAMF1 ligation.
• Assessment of drug resistance in SLAMF1-deficient CLL cells.

Main Results:

• SLAMF1 expression loss is observed in a subset of aggressive CLL patients, correlating with shorter time to treatment and reduced survival.
• SLAMF1 silencing in Mec-1 cells altered pathways involved in cell migration and vesicle trafficking.
• SLAMF1 deficiency increased CXCR4, CD38, and CD44 expression, enhancing chemotaxis.
• SLAMF1 ligation induced ROS accumulation, p38/JNK phosphorylation, and promoted autophagy by facilitating Beclin1-VPS34 complex formation.
• SLAMF1-silenced or SLAMF1(lo) CLL cells showed resistance to fludarabine and ABT-737.

Conclusions:

• Loss of SLAMF1 in CLL modulates pathways critical for cell migration and autophagy.
• These SLAMF1-associated pathway alterations may contribute to unfavorable clinical outcomes and affect therapeutic responses in CLL.
• SLAMF1 status could serve as a prognostic marker and influence treatment strategies in CLL.